# **Topical anticholinergic medications for primary**

# 2 hyperhidrosis: A protocol for a systematic review and

3 4

## meta-analysis

Yang Wu<sup>1+</sup>, Wenli Gao<sup>2+</sup>, Jiao Yan<sup>1</sup>, Min Yang<sup>1</sup>\*, Dongyang Gao<sup>3</sup>\*

5 1 Department of Integrated Chinese and Western Medicine, The General Hospital
6 of Western Theater Command, Chengdu, Sichuan, P.R. China.

7 2 Tianjin University of Traditional Chinese Medicine, Tianjin, China.

8 3 School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China.

9 \* Correspondence: translie@live.cn (M.Y.); 20200941085@bucm.edu.cn (D.G.)

+ These authors have contributed equally to this work and share first authorship.

## 12 Abstract

Background: Primary hyperhidrosis (PHH) is a chronic condition characterized by 13 14 excessive sweating. Several topical anticholinergic agents have been developed, but 15 the evidence for the efficacy and tolerability of changing medication pathways of 16 anticholinergics for PHH is limited. We will review the available literature to derive information regarding the efficacy and safety of different medicines used for the 17 18 topical treatment of patients with hyperhidrosis. Methods: PubMed, Cochrane 19 Library, Embase, Web of Science, and Cochrane Central Register of Controlled Trials 20 will be searched from inception to May 2023 for studies that may be eligible for 21 inclusion. Randomized controlled trials (RCTs) of PHH treated with topical 22 anticholinergic drugs will be included in the analysis. The primary outcomes will 23 include the severity of hyperhidrosis measured quantitatively, the Hyperhidrosis 24 Disease Severity Scale (HDSS) score, or the proportion of subjects with a minimum 25 2-grade improvement from baseline in HDSS, the Hyperhidrosis Disease Severity

It is made available under a CC-BY-NC 4.0 International license .

26	Measure-Axillary (HDSM-Ax) score, and Dermatology Life Quality Index (DLQI).
27	The secondary outcomes will focus on safety and tolerability. Study selection, data
28	extraction, and assessment of the risk of bias will be independently performed by two
29	investigators. Data synthesis will be performed using Review Manager 5.4 software.
30	Results: The results will be published as a peer-reviewed article. Conclusions: This
31	review will systematically evaluate the existing evidence on the efficacy and safety of
32	topical anticholinergic agents in the treatment of PHH. These conclusions will provide
33	supporting evidence for the current guidelines and more reliable evidence-based
34	medicine references for clinical practitioners and researchers.
35	PROSPERO registration number: CRD42022312316

Keywords: Primary hyperhidrosis; anticholinergic drugs; topical; systematic review
 37

# 38 Introduction

39 Hyperhidrosis (HH) is a chronic disease in which the degree of sweating exceeds the 40 physiological requirements for maintaining internal temperature regulation [1, 2]. HH 41 is characterized by excessive local or systemic sweating due to exocrine sweat gland 42 hyperfunction [3, 4], commonly found in areas such as axillae, palms, soles, and face 43 [5, 6]. Hyperhidrosis is divided into primary hyperhidrosis (PHH) and secondary 44 hyperhidrosis, based on whether there is an underlying disease or drug use [2, 7]. The 45 prevalence of HH ranges from 1% to 4.8% [8, 9], and is seen in both in children and 46 adults. The average age of onset is 14-25 years [10]. The discomfort associated with 47 severe hyperhidrosis can interfere with daily life and even lead to social and work

It is made available under a CC-BY-NC 4.0 International license .

48 isolation [11-13], with significant negative effects on the patient's daily activities,

49 mental health, and professional behavior [14, 15].

50	The pathophysiology, diagnosis, and treatment of PHH have attracted considerable
51	attention. Perspiration is produced by the secretion of sweat glands innervated by the
52	cholinergic nerve fibers of the sympathetic nervous system [16]. Studies suggest that
53	hyperactivity of cholinergic nerve fibers in sweat glands may lead to PHH [17]. In
54	addition, an excessive number or abnormal distribution of sweat glands may also be
55	the cause of the disease [18]. The anterior cingulate cortex, which controls responses
56	to emotional stimuli, also exerts a significant influence [19].
57	Management of PHH includes systemic, local, psychological, and surgical treatments.
58	[16] Systemic therapies include oral anticholinergic drugs [20] such as oxybutynin
59	[21]. Topical treatment includes the use of alumina, which chemically blocks sweat
60	ducts to reduce sweating [22], as well as topical anticholinergic agents, such as
61	glycopyrronium bromide. Ion import at specific sites is usually the treatment of
62	choice for HH of the palms and soles, but long-term maintenance treatment is
63	required [23]. Botulinum toxin type A (Botox, approved by the Food and Drug
64	Administration (FDA) in 2004 [6] and subsequently by several countries [24] is the
65	first- or second-line treatment option for axillary and plantar hyperhidrosis [25]. This
66	toxin blocks cholinergic stimulation of sweat glands. Psychotherapy is beneficial in
67	some cases [26, 27]. Surgery, including local surgery and endoscopic thoracic
68	sympathetic nerve resection, can be considered when conservative treatment fails [7,
69	28].

It is made available under a CC-BY-NC 4.0 International license .

70	However, these treatments are associated with side effects and complications.
71	Adverse events associated with oral anticholinergics, such as dry mouth, urinary
72	retention, constipation, and headache [29], often lead to interruption of drug use and
73	even increase the risk of cognitive impairment [30]. Studies have shown that its
74	efficacy decreases with long-term treatment [31]. Other adverse effects include skin
75	irritation, pain, and burns caused by ion import [32], repeated injections of Botox [16],
76	and compensatory sweating after sympathetic nerve resection [33, 34].
77	Therefore, improving the tolerability of preparations has become the focus of research,
78	especially in the development of preparations for external use [35]. Several topical
79	anticholinergic drugs have been approved in recent years. Glycopyrronium tosylate
80	(Qbrexza <sup>TM</sup> , a pre-wetting cloth containing 2.4% glycopyrronium solution) reduces
81	sweating by blocking the activation of acetylcholine receptors in the peripheral sweat
82	glands [15] and was approved by the FDA in 2018 [36]. Topical sofpironium
83	bromide(ECCLOCK®, 5%) gel reduces sweat secretion by inhibiting local sweat
84	gland M3 muscarinic receptor [37], it was approved in Japan in September 2020. In
85	addition, topical oxybutynin chloride cream or gel formulations have shown good
86	tolerability, and promise to be of benefit in the future [38]. Topical preparation of
87	glycopyrronium bromide has aroused interest as a treatment option for PHH [39], and
88	1% glycopyrronium bromide cream has completed the phase IIIa study [40]. The
89	dermal preparation of umeclidinium ammonium bromide is also under way [41].
90	Previous meta-analyses have assessed the efficacy and safety of oral anticholinergic
91	agents (oxybutynin, methane bromide, glycopyrrolate, etc.) for the treatment of PHH

It is made available under a CC-BY-NC 4.0 International license .

92 and have shown that improved outcomes are associated with a large number of 93 adverse events [5]. There are currently several topical anticholinergic agents on the 94 market, and the evidence for the efficacy and tolerability of a change in the route of 95 administration in the treatment of PHH has not been thoroughly evaluated. Therefore, 96 systematic reviews and meta-analyses are necessary to provide supporting evidence 97 for the current guidelines and more reliable evidence-based medicine references for 98 clinical practitioners and researchers.

## **99** Materials and Methods

### 100 Study registration

101 This meta-analysis protocol follows the Preferred Reporting Items for Systematic 102 Review and Meta-Analysis Protocols (PRISMA-P) [42] and the Manual for 103 Systematic Evaluation of Cochrane Interventions. The PRISMA-P checklist is in S1 104 Appendix. The protocol has been registered with the International Prospective 105 Register of Systematic Reviews (PROSPERO) (CRD42022312316). The 106 investigators will receive consistent training to ensure that they are familiar with the 107 background, purpose, and methodology of the system evaluation.

108 Eligibility criteria

### 109 **Type of studies**

110 Randomized controlled trials (RCTs) of PHH treated with topical anticholinergic

- 111 drugs will be included. Completed trials published on a clinical trial registration
- 112 platform will also be included. Quasi-randomized trials will be excluded.

### 113 **Types of participants**

It is made available under a CC-BY-NC 4.0 International license .

114	Participants with a diagnosis of primary hyperhidrosis based on focal, visible,
115	excessive sweating for at least 6 months without apparent cause, and meeting two or
116	more of the following criteria at the same time: (1) onset age of 25 years or younger,
117	(2) bilateral and relatively symmetric distribution, (3) at least one episode weekly, (4)
118	cessation of sweating during sleep, (5) impaired daily activities, and (6) family history
119	of primary hyperhidrosis will be included. Participants will have to have a
120	hyperhidrosis disease severity scale (HDSS) score of at least three during the baseline
121	evaluation.
122	Patients with secondary hyperhidrosis will be excluded from this study. Patients will
123	be excluded if they have another concurrent cutaneous or subcutaneous disease or if
124	they have received any treatment or undergone any procedure that could interfere with
125	drug activity.
126	Type of interventions and controls
127	
	RCTs comparing topical anticholinergics such as glycopyrronium tosylate,
128	sofpironium bromide, umeclidinium, or oxybutinin with placebo, and RCTs
128 129	
	sofpironium bromide, umeclidinium, or oxybutinin with placebo, and RCTs

therapy (e.g., a combination of topical and oral anticholinergic drugs) will beexcluded.

## 134 **Type of outcome measures**

It is made available under a CC-BY-NC 4.0 International license .

Primary outcomes: (1) Severity of hyperhidrosis measured quantitatively (e.g.,
gravimetry, evaporimeter, and minor starch-iodine test). (2) Hyperhidrosis Disease
Severity Scale (HDSS) score or the proportion of subjects with a minimum 2-grade
improvement from baseline in the HDSS. (3) Hyperhidrosis Disease Severity
Measure-Axillary (HDSM-Ax) score. (4) Dermatology Life Quality Index (DLQI).

140 Secondary outcomes: Safety and tolerability will be evaluated using the following 141 outcomes: (1) total number of patients who experienced treatment-emergent adverse 142 events (TEAEs) such as blurred vision or mydriasis, dry mouth, urinary retention, 143 constipation, anhidrosis, dizziness, headache, nasopharyngitis, etc.; (2) total number 144 of patients who experienced local skin reactions (LSRs), including burning, stinging, 145 pruritus, edema, erythema, dryness, and scaling; and (3) total number of patients who 146 experienced serious adverse events(according to the classification employed by the 147 US FDA).

#### 148 Data sources and search strategies

PubMed, Cochrane Library, Embase, Web of Science, and Cochrane Central Register of Controlled Trials will be searched from inception to May 2023 for studies that may be eligible for inclusion. In addition, we will identify other studies that meet the inclusion criteria from the list of references included in the study. Clinical trial registries, such as clinicaltrials.gov and WHO ICTRP, will also be searched for ongoing or unpublished clinical trials.

Two investigators (YW and WG) independently searched the literature using a combination of medical subject heading (MeSH) terms and free-text terms, and

It is made available under a CC-BY-NC 4.0 International license .

157 designed a search formula for each electronic database, including "hyperhidrosis,"

158 "anticholinergic drugs," and "randomized controlled trials". There were no language

159 restrictions in the search process. PubMed's search strategy is shown in S2 Appendix

and will be modified to meet the needs of other databases.

### 161 Studies selection

162 The literature will be screened independently by two investigators (YW and WG) 163 according to pre-established inclusion and exclusion criteria. The search results will 164 be imported into Endnote X9.0, and duplicated data will be deleted. The titles and 165 abstracts of the studies were read independently to screen out irrelevant studies and 166 records. The full paper will then be read and non-randomized controlled trials, 167 unqualified controls, and duplicate studies will be excluded. Any discrepancies in the 168 screening process will be resolved through discussion with a third investigator (DG). 169 The details of study selection are summarized in a flow chart (Figure 1).

#### 170 **Data extraction and management**

171 Two investigators (WG and JY) independently extracted the data using standard 172 Excel spreadsheets, including the first author, year of publication, country, research 173 type, research design, baseline information for each group, intervention, treatment 174 time, outcome indicators, and adverse reactions. The extracted data will be 175 crosschecked. If there is any discrepancy, the original article will be checked and the 176 discrepancy resolved by consensus. When data are not reported in a usable format and 177 are difficult to reliably extract, the authors will be contacted by email for information 178 twice over four weeks. If some data are still not available from authors, they can be

It is made available under a CC-BY-NC 4.0 International license .

- 179 acquired based on available data referring to advanced methods of data extraction,
- 180 such as intercepting data from a statistical graph and data conversion. [43]
- 181 Assessment of risk of bias

182 The Cochrane Risk Assessment of Bias Tool [44] will be applied by two investigators 183 (YW and WG) to independently assess the risk of bias in the included RCTs. The 184 assessment includes random sequence generation, allocation concealment, blinding of 185 participants and personnel, blinding of outcome assessment, incomplete outcome data, 186 selective reporting, and other biases. The criteria used to assess the risk of bias are 187 "low risk," "high risk" and "unclear [44]". Disagreements regarding the risk of bias 188 will be resolved by consultation with a third investigator (DG). A bias risk assessment 189 chart will be generated to present the assessment results and details.

190 Statistical analysis

191 Review Manager 5.4 software [42] (Copenhagen: The Nordic Cochrane Centre, The 192 Cochrane Collaboration) will be used for data synthesis and statistical analysis. For 193 dichotomous variables, relative risk (RR), risk difference (RD), 95% confidence 194 interval (CI), and P-values will be calculated. For continuous variables, the mean 195 difference (MD) or standard mean difference (SMD), 95% confidence interval (CI), 196 and P-values will be calculated using the random-effects model. Simultaneously, the 197 Q test and I2 index will be used to assess statistical heterogeneity. When 198 heterogeneity is significant (I2>50%), we will first explore the possible sources of 199 heterogeneity. A sensitivity analysis will be performed to examine the sources of 200 heterogeneity. When there is clinical or methodological heterogeneity, subgroup

It is made available under a CC-BY-NC 4.0 International license .

analysis or meta-regression(with Stata V.16.0 software) will be performed. [42] When
there is statistical heterogeneity, a random-effects model will be used. Finally, if
considerable heterogeneity cannot be resolved, a systematic review of descriptive
analyses will be performed instead of a meta-analysis.

205 Dealing with missing data

If there is missing data from the included RCT studies, the original articles, supplemental materials, and even other articles published based on the same trial will be scrutinized again for omissions. Otherwise, the investigators will attempt to contact the corresponding author of the study by email twice over 4 weeks. If complete data are not available, the study will not be included. The potential impact of missing data will be assessed using a sensitivity analysis, as described in the results.

#### 212 Subgroup analysis and sensitivity analysis

213 Subgroup analysis based on different comparisons and different skin sites (forehead, 214 axillae, palms, etc.) where the drugs are applied will be conducted. If there is 215 significant heterogeneity, the trials will be further classified to perform a subgroup 216 analysis after exploration. A sensitivity analysis will be performed to evaluate the 217 robustness of the results and to explore the source of heterogeneity. In addition, given 218 the different results between the same risk of bias domain of studies, studies can be 219 divided into different subgroups based on "low risk", "high risk of bias", and "not 220 clear" to compare the difference in the estimate of effect and analyze the contribution 221 of subgroups to the pooled effect size, which is conducive to grade the quality of 222 evidence.

It is made available under a CC-BY-NC 4.0 International license .

### 223 **Publication bias**

- 224 When more than 10 studies met the inclusion criteria, we will evaluate the potential
- 225 publication bias by drawing funnel plots (with Review Manager 5.4 software) and
- Egger tests (with Stata V.16.0 software).

### 227 Grading the quality of evidence

- 228 We will evaluate the evidence quality of the included studies according to the Grading
- 229 of Recommendations Assessment, Development, and Evaluation (GRADE) approach
- [45] The evidence quality GRADE is divided into four grades: high, moderate, low,
- and very low.

## 232 **Results**

233 The results of this systematic review will be published as a peer-reviewed article.

## 234 **Discussion**

Although there are many therapeutic options for PHH, treatment plans should be individualized according to the actual situation of patients[35]. Clinical guidelines for PHH no longer recommend systemic therapy because of unacceptable adverse reactions to oral anticholinergic drugs in recent years[46]. Topical anticholinergic agents optimize existing therapies and are likely to replace systemic oral administration[17].

This review will systematically evaluate the existing evidence on the efficacy and safety of topical anticholinergic agents in the treatment of PHH. These conclusions will help clinicians or practitioners to develop individual and more optimal treatment

It is made available under a CC-BY-NC 4.0 International license .

244 options for patients with PHH and provide supporting evidence for health 245 policymakers and the current guidelines.

#### Conclusions 246

247 This systematic review aims to provide comprehensive evidence on the efficacy and 248 safety of topical anticholinergic agents for primary hyperhidrosis. The findings of this 249 review may help point to better forms of treatment based on evidence-based medicine. 250

#### **Author Contributions:** 251

- 252 Conceptualization, D.G. and Y.W.; methodology, W.G.; software, D.G.; validation,
- 253 W.G., M.Y. and Y.W.; formal analysis, D.G.; investigation, Y.W.; resources, Y.W.;
- 254 data curation, W.G. and J.Y.; writing-original draft preparation, Y.W. and W.G.;
- 255 writing—review and editing, D.G.; visualization, D.G.; supervision, M.Y.; project
- 256 administration, M.Y.; funding acquisition, M.Y. All authors have read and agreed to
- 257 the published version of the manuscript."

#### **Funding:** 258

- 259 This work was supported by the Hospital Management Project of the General Hospital
- 260 of Western Theater Command, Grant Number: 2021-XZYG-B34. The sponsor and
- 261 funder had and will not have a role in the study design, data collection, and analysis.
- **Competing interests**: None declared. 262

#### **Author information:** 263

- 264 Yang Wu (first author): Ph.D. Email: <u>betteryy@126.com</u>.
- 265 Wenli Gao(first author): Dr. Email: 18406564543@163.com

It is made available under a CC-BY-NC 4.0 International license .

266	Dongyang	Gao	(Correspondence	author):	Ph.D.	Email:
-----	----------	-----	-----------------	----------	-------	--------

- 267 <u>20200941085@bucm.edu.cn</u>
- 268 Min Yang(Correspondence author): Ph.D. Email: translie@live.cn
- 269 Jiao Yan: Dr. Email: <u>312859465@qq.com</u>
- 270
- 271 **References** :
- 272 1. Caserta F, Lenn J, Hofland H. Variables Affecting Delivery of Glycopyrronium Tosylate
- 273 Through Human Skin In Vitro. J Drugs Dermatol. 2020;19(11):1080-5. Epub 2020/11/17. doi:
- 274 10.36849/jdd.2020.5062. PubMed PMID: 33196749.
- 275 2. Liu V, Farshchian M, Potts GA. Management of Primary Focal Hyperhidrosis: An
- 276 Algorithmic Approach. J Drugs Dermatol. 2021;20(5):523-8. Epub 2021/05/04. doi:
- 277 10.36849/jdd.5774. PubMed PMID: 33938689.
- 278 3. Wolosker N, Kauffman P, de Campos JRM, Faustino CB, da Silva MFA, Teivelis MP, et al.
- 279 Long-term results of the treatment of primary hyperhidrosis with oxybutynin: follow-up of 1,658
- 280 cases. Int J Dermatol. 2020;59(6):709-15. Epub 2020/04/18. doi: 10.1111/ijd.14872. PubMed
- 281 PMID: 32301117.
- 4. Basedow S, Kruse R, Bruch-Gerharz D. [Hyperhidrosis of childhood and adolescence:
  clinical aspects and therapeutic options]. Hautarzt. 2011;62(12):928-34. Epub 2011/10/12. doi:
- 284 10.1007/s00105-011-2225-7. PubMed PMID: 21987173.
- Cruddas L, Baker DM. Treatment of primary hyperhidrosis with oral anticholinergic
   medications: a systematic review. J Eur Acad Dermatol Venereol. 2017;31(6):952-63. Epub
   2016/12/16. doi: 10.1111/jdv.14081. PubMed PMID: 27976476.

It is made available under a CC-BY-NC 4.0 International license .

288	6. Cohen JL, Cohen G, Solish N, Murray CA. Diagnosis, impact, and management of focal				
289	hyperhidrosis: treatment review including botulinum toxin therapy. Facial Plast Surg Clin North				
290	Am. 2007;15(1):17-30, v-vi. Epub 2007/02/24. doi: 10.1016/j.fsc.2006.10.002. PubMed PMID:				
291	17317552.				
292	7. McConaghy JR, Fosselman D. Hyperhidrosis: Management Options. Am Fam Physician.				
293	2018;97(11):729-34. Epub 2018/09/15. PubMed PMID: 30215934.				
294	8. Delort S, Marchi E, Corrêa MA. Oxybutynin as an alternative treatment for hyperhidrosis.				
295	An Bras Dermatol. 2017;92(2):217-20. Epub 2017/05/26. doi:				
296	10.1590/abd1806-4841.201755126. PubMed PMID: 28538882; PubMed Central PMCID:				
297	PMCPMC5429108.				
298	9. Ram R, Lowe NJ, Yamauchi PS. Current and emerging therapeutic modalities for				
299	hyperhidrosis, part 1: conservative and noninvasive treatments. Cutis. 2007;79(3):211-7. Epub				
300	2007/08/07. PubMed PMID: 17674587.				
301	10. Kumar MG, Foreman RS, Berk DR, Bayliss SJ. Oral glycopyrrolate for refractory pediatric				
302	and adolescent hyperhidrosis. Pediatr Dermatol. 2014;31(1):e28-30. Epub 2013/11/26. doi:				
303	10.1111/pde.12236. PubMed PMID: 24266878.				
304	11. Callejas MA, Grimalt R, Cladellas E. [Hyperhydrosis update]. Actas Dermosifiliogr.				
305	2010;101(2):110-8. Epub 2010/03/13. doi: 10.1016/j.ad.2009.09.004. PubMed PMID:				
306	20223153.				
307	12. Bajaj V, Langtry JA. Use of oral glycopyrronium bromide in hyperhidrosis. Br J Dermatol.				
308	2007;157(1):118-21. Epub 2007/04/27. doi: 10.1111/j.1365-2133.2007.07884.x. PubMed				
309	PMID: 17459043.				

It is made available under a CC-BY-NC 4.0 International license .

310	13. Nyamekye IK. Current therapeutic options for treating primary hyperhidrosis. Eur J Vasc
311	Endovasc Surg. 2004;27(6):571-6. Epub 2004/05/04. doi: 10.1016/j.ejvs.2004.01.023.
312	PubMed PMID: 15121105.
313	14. Rzany B, Müller C, Hund M. [Focal hyperhidrosis.Quality of life, socioeconomic
314	importance and use of internal medicinal therapy]. Hautarzt. 2012;63(6):456-61. Epub
315	2012/06/20. doi: 10.1007/s00105-012-2331-1. PubMed PMID: 22710840.
316	15. Nwannunu CE, Limmer AL, Coleman K, Shah R, Patel RR, Mui UN, et al. Glycopyrronium
317	Tosylate (Qbrexza) for Hyperhidrosis. Skin Therapy Lett. 2019;24(2):1-3. Epub 2019/04/11.
318	PubMed PMID: 30970203.
319	16. Connolly M, de Berker D. Management of primary hyperhidrosis: a summary of the
320	different treatment modalities. Am J Clin Dermatol. 2003;4(10):681-97. Epub 2003/09/26. doi:
321	10.2165/00128071-200304100-00003. PubMed PMID: 14507230.
322	17. Wechter T, Feldman SR, Taylor SL. The Treatment of Primary Focal Hyperhidrosis. Skin
323	Therapy Lett. 2019;24(1):1-7. Epub 2019/03/01. PubMed PMID: 30817880.
324	18. Sammons JE, Khachemoune A. Axillary hyperhidrosis: a focused review. J Dermatolog
325	Treat. 2017;28(7):582-90. Epub 2017/03/21. doi: 10.1080/09546634.2017.1309347. PubMed
326	PMID: 28318360.
327	19. Eisenach JH, Atkinson JL, Fealey RD. Hyperhidrosis: evolving therapies for a
328	well-established phenomenon. Mayo Clin Proc. 2005;80(5):657-66. Epub 2005/05/13. doi:
329	10.4065/80.5.657. PubMed PMID: 15887434.
330	20. Baumgartner FJ, Bertin S, Konecny J. Superiority of thoracoscopic sympathectomy over
331	medical management for the palmoplantar subset of severe hyperhidrosis. Ann Vasc Surg.

It is made available under a CC-BY-NC 4.0 International license .

2009;23(1):1-7. Epub 2008/07/16. doi: 10.1016/j.avsg.2008.04.014. PubMed PMID:

333	18619780.
334	21. Nicholas R, Quddus A, Baker DM. Treatment of Primary Craniofacial Hyperhidrosis: A
335	Systematic Review. Am J Clin Dermatol. 2015;16(5):361-70. Epub 2015/06/10. doi:
336	10.1007/s40257-015-0136-6. PubMed PMID: 26055729.
337	22. Pariser DM, Ballard A. Topical therapies in hyperhidrosis care. Dermatol Clin.
338	2014;32(4):485-90. Epub 2014/08/26. doi: 10.1016/j.det.2014.06.008. PubMed PMID:
339	25152341.
340	23. Kim WO, Kil HK, Yoon DM, Cho MJ. Treatment of compensatory gustatory hyperhidrosis
341	with topical glycopyrrolate. Yonsei Med J. 2003;44(4):579-82. Epub 2003/09/02. doi:
342	10.3349/ymj.2003.44.4.579. PubMed PMID: 12950111.
343	24. Murray CA, Cohen JL, Solish N. Treatment of focal hyperhidrosis. J Cutan Med Surg.
344	2007;11(2):67-77. Epub 2007/03/22. doi: 10.2310/7750.2007.00012. PubMed PMID:
345	17374317.
346	25. Reisfeld R, Berliner Kl. Evidence-based review of the nonsurgical management of
347	hyperhidrosis. Thorac Surg Clin. 2008;18(2):157-66. Epub 2008/06/19. doi:
348	10.1016/j.thorsurg.2008.01.004. PubMed PMID: 18557589.
349	26. Glaser DA, Hebert AA, Pariser DM, Solish N. Primary focal hyperhidrosis: scope of the
350	problem. Cutis. 2007;79(5 Suppl):5-17. Epub 2007/06/29. PubMed PMID: 17596096.

- 351 27. Maillard H, Lecouflet M. [Management of hyperhidrosis]. Ann Dermatol Venereol.
- 352 2015;142(4):252-61. Epub 2015/02/24. doi: 10.1016/j.annder.2014.11.005. PubMed PMID:
- 353 25697587

332

It is made available under a CC-BY-NC 4.0 International license .

354	28. Nawrocki S, Cha J. The etiology, diagnosis, and management of hyperhidrosis: A
355	comprehensive review: Therapeutic options. J Am Acad Dermatol. 2019;81(3):669-80. Epub
356	2019/02/03. doi: 10.1016/j.jaad.2018.11.066. PubMed PMID: 30710603.
357	29. Campanati A, Gregoriou S, Consales V, Rizzetto G, Bobyr I, Diotallevi F, et al. Combined
358	treatment of palmar hyperhidrosis with botulinum toxin type A and oxybutynin chloride: Results
359	of a clinical, multicenter, prospective study. Dermatologic Therapy. 2020;33(6):e14039. doi:
360	10.1111/dth.14039. PubMed PMID: 32691938.
361	30. Gregoriou S, Kontochristopoulos G, Tiligada E. Pharmacokinetic profile data of
362	glycopyrronium bromide 1% cream beyond 2 weeks are important. The British Journal of
363	Dermatology. 2021;185(2):467-8. doi: 10.1111/bjd.20088. PubMed PMID: 33792896.
364	31. Del Boz Gonzalez J, Rodríguez Barón D, Millán-Cayetano JF, de Troya Martin M.
365	Tolerance of oral oxybutynin in the treatment of hyperhidrosis. Dermatol Ther.
366	2020;33(6):e14197. Epub 2020/08/15. doi: 10.1111/dth.14197. PubMed PMID: 32794595.
367	32. Shimizu H, Tamada Y, Shimizu J, Ohshima Y, Matsumoto Y, Sugenoya J. Effectiveness
368	of iontophoresis with alternating current (AC) in the treatment of patients with palmoplantar
369	hyperhidrosis. J Dermatol. 2003;30(6):444-9. Epub 2003/06/18. doi:
370	10.1111/j.1346-8138.2003.tb00414.x. PubMed PMID: 12810991.
371	33. Cladellas E, Callejas MA, Grimalt R. A medical alternative to the treatment of
372	compensatory sweating. Dermatol Ther. 2008;21(5):406-8. Epub 2008/10/11. doi:
373	10.1111/j.1529-8019.2008.00222.x. PubMed PMID: 18844718.
374	34. Costa Ada S, Jr., Leão LE, Succi JE, Perfeito JA, Filho Castelo A, Rymkiewicz E, et al.

375 Randomized trial - oxybutynin for treatment of persistent plantar hyperhidrosis in women after

medRxiv preprint doi: https://doi.org/10.1101/2022.03.05.22271966; this version posted December 28, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

376 sympathectomy. Clinics (Sao Paulo). 2014;69(2):101-5. Epub 2014/02/13. doi:
377 10.6061/clinics/2014(02)05. PubMed PMID: 24519200; PubMed Central PMCID:
378 PMCPMC3912338.

379 35. Brown AL, Gordon J, Hill S. Hyperhidrosis: review of recent advances and new
380 therapeutic options for primary hyperhidrosis. Curr Opin Pediatr. 2014;26(4):460-5. Epub
381 2014/06/07. doi: 10.1097/mop.00000000000000108. PubMed PMID: 24905102.

382 36. Glaser DA, Hebert AA, Nast A, Werschler WP, Green L, Mamelok RD, et al. A 44-Week 383 Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in 384 Patients with Primary Axillary Hyperhidrosis. Am J Clin Dermatol. 2019;20(4):593-604. Epub 385 2019/05/22. doi: 10.1007/s40257-019-00446-6. PubMed PMID: 31111409; PubMed Central 386 PMCID: PMCPMC6687675 Biotech. Inc., Dermira, Inc., Evolus, and Sienna 387 Biopharmaceuticals, Inc. and a consultant for Dermira, Inc. William P. Werschler is a 388 consultant and investigator for Dermira, Inc. Adelaide A. Herbert is a consultant for Dermira, 389 Inc. and an employee of the UTHealth McGovern Medical School, which received 390 compensation from Dermira, Inc. for study participation. Alexander Nast is an employee of 391 Charité - Universitätsmedizin Berlin, which received compensation from Dermira, Inc. for 392 study participation; he was an advisory board member for Boehringer Ingelheim, carried out 393 educational activities for Bayer and Novartis, and received research grants from Eli Lilly and 394 Company, Pfizer, GSK, Plc., and MEDA. Lawrence Green is an investigator for Brickell 395 Biotech, Inc. and an advisory board member and investigator for Dermira, Inc. Richard D. 396 Mamelok is a consultant for Dermira, Inc. John Quiring is an employee of QST Consultations. 397 Janice Drew is an employee of Dermira, Inc. David M. Pariser is a consultant and investigator

It is made available under a	I CC-B	Y-NC 4.0	International	license
------------------------------	--------	----------	---------------	---------

398	for Brickell Biotech, Inc., Celgene Corporation, Dermira, Inc., LEO Pharma US, Novartis
399	Pharmaceuticals, Promius Pharmaceuticals, Regeneron, and Valeant Pharmaceuticals
400	International, a consultant for ATACAMA, Biofrontera AG, DUSA Pharmaceuticals, Inc., Sonofi,
401	TDM SurgiTech, Inc., and TheraVida, and an investigator for Abbott Laboratories, Amgen,
402	Asana Biosciences, Dermavant Sciences, Eli Lilly and Company, Merck & Co., Inc., Novo
403	Nordisk A/S, Ortho Dermatologics, Peplin Inc., Pfizer Inc., Photocure ASA, and Stiefel (as
404	GSK company).
405	37. Paik J. Sofpironium Bromide: First Approval. Drugs. 2020;80(18):1981-6. Epub
406	2020/11/26. doi: 10.1007/s40265-020-01438-1. PubMed PMID: 33236266.
407	38. Kontochristopoulos G, Markantoni V, Agiasofitou E, Platsidaki E, Kouris A, Campanati A,
408	et al. Treatment of primary axillary hyperhidrosis with a cream formulation of oxybutynin
409	chloride 10. Journal of the European Academy of Dermatology and Venereology : JEADV.
410	2021;35(8):e524-e6. doi: 10.1111/jdv.17297. PubMed PMID: 33893675.
411	39. Chabicovsky M, Winkler S, Soeberdt M, Kilic A, Masur C, Abels C. Pharmacology,
412	toxicology and clinical safety of glycopyrrolate. Toxicol Appl Pharmacol. 2019;370:154-69.
413	Epub 2019/03/25. doi: 10.1016/j.taap.2019.03.016. PubMed PMID: 30905688.
414	40. Abels C, Soeberdt M, Kilic A, Reich H, Knie U, Jourdan C, et al. A glycopyrronium
415	bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety
416	results from a phase IIIa randomized controlled trial. The British journal of dermatology.
417	2021;185(2):315-22. doi: 10.1111/bjd.19810. PubMed PMID: 33445205.
418	41. Nasir A, Bissonnette R, Maari C, DuBois J, Pene Dumitrescu T, Haddad J, et al. A phase

419 2a randomized controlled study to evaluate the pharmacokinetic, safety, tolerability and clinical

It is made available under a CC-BY-NC 4.0 International license .

420	effect of topically applied Umeclidinium in subjects with primary axillary hyperhidrosis. J Eur
421	Acad Dermatol Venereol. 2018;32(1):145-51. Epub 2017/10/22. doi: 10.1111/jdv.14651.
422	PubMed PMID: 29055158.
423	42. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred
424	reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015:
425	elaboration and explanation. BMJ (Clinical research ed). 2015;350:g7647. doi:
426	10.1136/bmj.g7647. PubMed PMID: 25555855.
427	43. Liu HN WH, Yao C, Chen YZ, Liu TT. Advanced methods of data extraction for

- 428 continuous outcomes in meta-analysis. Chinese Journal of Evidence-based Medicine. 429 2017;17(01):117-21.
- 430 44. Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance
- 431 for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic
- 432 Reviews of Interventions. The Cochrane database of systematic reviews. 2019;10:ED000142.
- 433 doi: 10.1002/14651858.ED000142. PubMed PMID: 31643080.
- 434 45. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE:
- 435 an emerging consensus on rating quality of evidence and strength of recommendations. BMJ
- 436 (Clinical research ed). 2008;336(7650):924-6. doi: 10.1136/bmj.39489.470347.AD. PubMed
- 437 PMID: 18436948.
- 438 46. del Boz J. Systemic treatment of hyperhidrosis. Actas Dermosifiliogr. 2015;106(4):271-7.
- 439 Epub 2015/02/02. doi: 10.1016/j.ad.2014.11.012. PubMed PMID: 25638324.

# 440 **Supporting information**

441 S1 Appendix. The PRISMA-P checklist.

It is made available under a CC-BY-NC 4.0 International license .

- 442 S2 Appendix. The search strategy for PubMed.
- 443 S1 Fig. The PRISMA flow diagram of the study selection process.

It is made available under a CC-BY-NC 4.0 International license .

